Carastock.

Sep 18, 2023 · The 39 rating InvestorsObserver gives to Cara Therapeutics Inc ( CARA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 41 percent of stocks in the Biotechnology industry, CARA’s 39 overall rating means the stock scores better than 39 percent of all stocks. CARA has an Overall Score of 39. The stock of Cara Therapeutics Inc. (CARA) has gone down by -0.88% for the week, with a -19.04% drop in the past month and a -41.67% drop in the past quarter. The volatility ratio for the week is 6.06%, and the volatility levels for the past 30 days are 7.16% for CARA. The simple moving average forMay 25, 2023 · Simply Wall St. May 25, 2023 at 6:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid ... Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...The current Cara Therapeutics [ CARA] share price is $1.09. The Score for CARA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults ...The firm currently boasts a market capitalization value of $187.83 million alongside a price-earnings ratio of -2.23 and beta of 0.87. Nonetheless, with exponential growth attainable through various regulatory approvals, the research-based biopharmaceutical company appears primed to deliver cutting-edge solutions that …

Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of ...

Shutterstock is a global marketplace for artists and creators to sell royalty-free images, footage, vectors and illustrations. We want to see the world through your eyes.Get the latest Cara Therapeutics, Inc. (CARA) stock news and headlines to help you in your trading and investing decisions.Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.CARA 9.28%. 39. See CARA Report. The 37 rating InvestorsObserver gives to Cara Therapeutics Inc ( CARA) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 31 percent of stocks in the Biotechnology industry, CARA’s 37 overall rating means the stock scores better than 37 percent of all stocks.

The stock of Cara Therapeutics Inc (CARA) has seen a -11.28% decrease in the past week, with a -16.90% drop in the past month, and a -60.67% decrease in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.66% for CARA.

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate …

12 thg 2, 2014 ... Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, ...NasdaqGM:CARA Stock Report. Mkt Cap: US$52.2m. Add to watchlist. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial Health; 5 Dividend; 6 Management; 7 Ownership; Other Information; View Management. Cara Therapeutics Ownership. Who are the major shareholders and have insiders been buying or selling?Overview. Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational ...Dec 1, 2023 · Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults ... What's Happening With CARA Stock Today? Cara Therapeutics Inc (CARA) stock is trading at $5.05 as of 2:41 PM on Friday, Mar 31, an increase of $0.16, or 3.27% from the previous closing price of $4.89. The stock has traded between $4.90 and $5.06 so far today.Cara Therapeutics, Inc. (CARA) stock forecast and price target Find the latest Cara Therapeutics, Inc. CARA analyst stock forecast, price target, and recommendation trends with in-depth analysis ...

Interactive Chart for Cara Therapeutics, Inc. (CARA), analyze all the data with a huge range of indicators.Cara Therapeutics (CARA) Company Description. Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic ... Get the latest Cara Therapeutics Inc. (CARA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Dec 1, 2023 · Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of 1,327.36%. The lowest target is $1.00 and the highest is $28. On average, analysts rate CARA stock stock as a strong buy. Dec 1, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00. CARA Stock 12 Months Forecast. $14.10. (1230.19% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $14.10 with a high forecast of $25.00 and a low forecast of $3.50. The average price target represents a 1230.19% change from the last price of $1.06.Dec 1, 2023 · Compare with up to 5 Stocks. On Friday morning 12/01/2023 the Cara Therapeutics Inc share started trading at the price of $0.96. Compared to the closing price on Thursday 11/30/2023 on NAS of $0. ...

Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.

12 thg 3, 2018 ... Cara Operations, which also owns Swiss Chalet, saw sales grow 13.5 per cent in the fourth quarter to $774.9 million.CARA U.S.: Nasdaq Cara Therapeutics Inc. Watch NEW Set a price target alert Premarket Last Updated: Nov 28, 2023 6:54 a.m. EST Delayed quote $ 1.0000 0.07 7.37% Before Hours Volume: 1 Advanced...BRKR Vs CARA: Stock comparison by Artificial Intelligence. Which is a better buy? Make smart data-driven investment decisions and get unique insights. Start now and save 50% for the first 3 months save 50% for the first 3 months. Ticker. Company. Your search produced no matches. We currently support US stocks and STOXX Europe 600 …Cara Therapeutics Inc (CARA) stock is trading at $4.98 as of 3:31 PM on Thursday, Mar 23, a decline of -$0.20, or -3.86% from the previous closing price of $5.18. The stock has traded between $4.94 and $5.33 so far today. Volume today is below average. So far 419,735 shares have traded compared to average volume of 832,550 shares.Nov 13, 2013 · A high-level overview of Cara Therapeutics, Inc. (CARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Cara Therapeutics stock price fell by -1.90% on the last day (Wednesday, 29th Nov 2023) from $0.98 to $0.96. During the last trading day the stock fluctuated 7.37% from a day low at $0.95 to a day high of $1.02. The price has fallen in 6 of the last 10 days and is down by -12.47% for this period. Volume has increased on the last day by 227 ...

30 thg 4, 2021 ... Cara's stock tanks as atopic dermatitis phase 2 misses endpoint ... A phase 2 trial of Cara Therapeutics' anti-itch treatment has missed its ...

Cara Therapeutics, Inc. Common Stock. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is ...

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to ...Cara Therapeutics (CARA) Options Chain & Prices. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Get daily stock ideas from top-performing Wall Street analysts.Cara Therapeutics, Inc. (CARA) stock forecast and price target Find the latest Cara Therapeutics, Inc. CARA analyst stock forecast, price target, and recommendation trends with in-depth analysis ...Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate …Find the latest Cara Therapeutics, Inc. (CARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus.Cara Therapeutics, Inc. (CARA.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Cara Therapeutics, Inc. | Nasdaq: ...Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of ...This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Cara Therapeutics, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more. 1 minute.Aug 24, 2021 · Get the latest Cara Therapeutics Inc. (CARA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. 12 thg 2, 2014 ... Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, ...Cara Therapeutics' Q4 earnings EPS loss was $0.56 per share. Read why I am looking to quickly book some profits in CARA stock.

Institutional Ownership and Shareholders. Cara Therapeutics Inc (US:CARA) has 284 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 30,570,531 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, Disciplined Growth ...Find the latest news headlines from Cara Therapeutics, Inc. Common Stock (CARA) at Nasdaq.com.Pruritus is defined as an unpleasant sensation that provokes the desire to scratch, but we know it’s much more than that. Chronic pruritus can be a devastating, disabling, and burdensome condition that significantly impairs quality of life. The millions of people who suffer from pruritus deserve relief.Stock opname adalah aktivitas perhitungan jumlah stok barang atau produk yang menumpuk di gudang atau di toko sebelum barang tersebut. Yuk baca detailnya!Instagram:https://instagram. harrison financialconsumer discretionary etf vanguardbudwieser stockoptions profit calc The stock of Cara Therapeutics Inc (CARA) has seen a -11.28% decrease in the past week, with a -16.90% drop in the past month, and a -60.67% decrease in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.66% for CARA. cryptocurrency investment appshow to convert ira to gold finance.yahoo.com - November 14 at 5:00 PM. Cara Therapeutics Stock (NASDAQ:CARA) Earnings Dates and Earning Calls. benzinga.com - November 14 at 7:53 AM. Cara Therapeutics GAAP EPS of -$0.52 beats by $0.01, revenue of $4.87M misses by $5.08M. msn.com - November 13 at 8:53 PM.Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of ... dummy stock trading app Find the latest Cara Therapeutics, Inc. (CARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Cara Therapeutics Stock Earnings. The value each CARA share was expected to gain vs. the value that each CARA share actually gained. Cara Therapeutics ( CARA) reported Q3 2023 earnings per share (EPS) of -$0.52, meeting estimates of -$0.52 by 0.60%. In the same quarter last year, Cara Therapeutics 's earnings per share (EPS) was -$0.43.